



Center for Translational  
Molecular Medicine

Translating science into better healthcare

# Using SMAA to assess the cost effectiveness of health care interventions: a case study in infertility treatment

Douwe Postmus, Tommi Tervonen, Hans Hillege, Erik Buskens

University Medical Center Groningen, The Netherlands



**umcg**

# Introduction


- In cost-effectiveness analysis (CEA), two or more medical interventions are evaluated in terms of their
  - Costs (e.g. hospitalization costs)
  - Effects (e.g. mean survival time)
- Using a fixed substitution rate  $\lambda$ , the consequences of each alternative are combined in a single outcome measure, called the net monetary benefit ( $NMB = \lambda * e - c$ )
- Decision support is provided by plotting for each possible value of  $\lambda$  the probability that an alternative has the highest NMB
  - => Cost-effectiveness acceptability curves (CEACs)

# Example: treatment and control

Treatment	Cost (x \$1,000)	Effect (life years)	Probability
	90	5	1/3
	110	4	1/3
	110	6	1/3

Control	Cost (x \$1,000)	Effect (life years)	Probability
	100	5	1

# Example cont'd: CEAC treatment



# Cost-effectiveness acceptability curves and their limitations

- CEACs only provide a partial picture of the uncertainty surrounding the decision problem:
  - it shows the probability of making the correct decision when a certain alternative is selected
  - it does NOT provide any information about the alternative's probability distribution over the other ranks when making a wrong decision
- Ignoring information about ranks other than the first one can make it difficult to identify good compromise solutions:
  - extreme alternatives look similar to those with good acceptabilities for the best ranks only

# SMAA-CEA

- To overcome the limitations associated with the CEAC, we have developed SMAA-CEA as a new method for representing decision uncertainty in CEA
- SMAA-CEA is based on stochastic multi-criteria acceptability analysis (SMAA), a family of methods for aiding multi-criteria group decision making
- These methods are based on exploring the weight space in order to describe the preferences that make each alternative the most preferred one, or that would give a certain rank for a specific alternative
- SMAA has successfully been applied in various real-life decision aiding contexts, including cargo harbor environmental impact assessment, elevator planning, and drug benefit-risk analysis

# Preliminaries

- Consider  $n$  health care interventions that are to be evaluated with respect to their costs ( $c$ ) and effects ( $e$ )
- It is assumed that the decision maker's preference structure can be represented by the NMB function

$$\text{NMB}(e, c, \lambda) = \lambda e - c$$

- The costs and effects of the different alternatives are uncertain and represented by the random vectors  $\mathbf{C} = [C_1, \dots, C_n]^T$  and  $\mathbf{E} = [E_1, \dots, E_n]^T$

# Preliminaries cont'd

- For given realizations  $\mathbf{c}$  of  $\mathbf{C}$  and  $\mathbf{e}$  of  $\mathbf{E}$ , the alternatives are ranked in descending order by means of a ranking function

$$\text{rank}(i, \mathbf{c}, \mathbf{e}, \lambda) = 1 + \sum_{k=1}^n I(\text{NMB}(e_k, c_k, \lambda) > \text{NMB}(e_i, c_i, \lambda))$$

- Define, based on this ranking function, the sets of favorable cost and effect measurements as

$$M_i^r(\lambda) = \{(c, e) \in R^n \times R^n : \text{rank}(i, \mathbf{c}, \mathbf{e}, \lambda) = r\}$$

- Any realization  $(c, e)$  in  $M_i^r(\lambda)$  results in such values for the different alternatives that alternative  $i$  obtains rank  $r$

# Rank acceptability indices

- The *rank acceptability index*  $b_i^r(\lambda)$  describes, for a given value of  $\lambda$ , the share of all possible realizations of  $\mathbf{C}$  and  $\mathbf{E}$  for which alternative  $i$  is ranked at place  $r$
- It is computed as a multidimensional integral over the consequence space as

$$b_i^r(\lambda) = \int \int_{(c,e) \in M_i^r(\lambda)} f_{CE}(\mathbf{c}, \mathbf{e}) d\mathbf{c} d\mathbf{e}$$

- By definition, an alternative's rank acceptability indices are within the interval  $[0,1]$ 
  - 0 indicates that the alternative will never indicate rank  $r$
  - 1 indicates that the alternative will obtain rank  $r$  for certain

# Cumulative rank acceptability indices

- Favorable alternatives are those with high acceptability indices for the best ranks and low acceptability indices for the worst ranks
- This information can be obtained from the *cumulative rank acceptability indices*

$$t_i^k(\lambda) = \sum_{r=1}^k b_i^r(\lambda)$$

- $t_i^k(\lambda)$  describes the fraction of all possible realizations of **C** and **E** for which alternative  $i$  is assigned at any of the  $k$  best ranks
  - $t_i^1(\lambda) = b_i^1(\lambda)$
  - $t_i^n(\lambda) = 1$

# Case study in IVF treatment selection

- To illustrate the use of the SMAA-CEA descriptive indices, we consider a previously published cost-effectiveness decision problem relating to infertility treatment (Fiddelaers et al., 2009)
- The objective of the original study was to compare the cost-effectiveness of seven IVF strategies based on a maximum of three consecutive IVF cycles and different combinations of embryo transfer policies per cycle
- For this purpose, an elaborate Markov cycle tree was developed, taking into account
  - canceled cycles,
  - availability of only one embryo (resulting in a so-called compulsory single embryo transfer),
  - declining pregnancy rates in subsequent cycles,
  - the possibility of having frozen embryo transfers when a patient did not achieve a pregnancy after fresh embryo transfer or had a miscarriage / stillborn child, and
  - treatment dropouts due to cycle cancellation or fertilization failure


# Case study in IVF treatment selection cont'd

- Effects were quantified in terms of the mean live birth probability for a couple starting IVF treatment
- Costs were analyzed from a societal perspective and included
  - the cost of IVF treatment,
  - the cost of a singleton and twin pregnancy,
  - the cost of delivery, and
  - the cost of the period from birth until sex weeks after birth
- Uncertainty was accounted for by specifying probability distributions for the model parameters


# Results of the probabilistic cost-effectiveness analysis

Strategy	Mean effect	Mean Cost	ICER	Dominated by
1. 3 x eSET	0.374	14,154		
2. eSET + 2 x STP	0.458	15,157		1-5
3. eSET + STP + DET	0.470	15,609		5
4. eSET + 2 x DET	0.490	16,423		5
5. 3 x STP	0.523	15,498	9,002	
6. STP + 2 x DET	0.552	16,567	38,488	
7. 3 x DET	0.575	11,700	46,560	


# Cost-effectiveness acceptability curves



# Cumulative rank acceptability curves for ranks 1 and 2



# Cumulative rank acceptability curves for ranks 1, 2, and 3




# Discussion

- When the value of  $\lambda$  is established a priori of the CEA, the general consensus is that a decision maker should select the alternative with the highest expected NMB
  - => The rank acceptability indices can be used to provide a complete picture of the uncertainty surrounding the treatment selection decision
- In many real-life decision problems, the value of  $\lambda$  is not exactly known by the decision maker
  - => The cumulative rank acceptability indices can be used to identify compromise alternatives that have reasonable cost-effectiveness profiles across wide  $\lambda$  ranges

# Conclusion

- By describing an intervention's rank distribution, the SMAA-CEA descriptive indices provide a complete picture of the uncertainty surrounding the cost-effectiveness decision problem
- We therefore believe that the (cumulative) rank acceptability curves will be a useful extension of the CEAC, which only provides information on the probability that a given intervention is the optimal one



CTMM - A public-private partnership  
for translational molecular medicine